## Contents

**Volume 75 Issue 6 | ARD June 2016**

### Editorials

947 Separately tackling the development of erosions with denosumab: ultimately closing a gap in the treatment of patients with rheumatoid arthritis or trying too hard too late?

P Verschueren, R Westhovens

950 Flare in axial spondyloarthritis. The dark side of the outcome

D Wendling, C Prati

### Viewpoint

952 Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force


### Criteria

958 Consensus classification criteria for paediatric Behcet’s disease from a prospective observational cohort: PEDBD

I Konu-Paati, F Shahram, M Dance-Bello, L Constans, R Cozzi, M Gattorno, J Anton, M Hoyer, B Chirrot, K Bouabdall, T Fogel-Titton, J Kuwert-Deschner, H Agostini, S Federici, A Amououx, C Picchione, S Ozem, the PEDBD group

### Recommendation

965 Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative


### Review

974 The changing landscape of biosimilars in rheumatology

T Denier, V Strand, P Cornelis, J Goncalves, L Caldas, J Kaye, T K Kost, J Smolarek, Y Tanaka, G R Burmester

### Clinical and epidemiological research

983 Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose–response study of AMG 162 (Denosumab) in patients with Rheumatoid arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial

T Takeuchi, Y Tanaka, N Ishiguro, H Yamamatake, T Yoneda, T Oishi, N Okubo, H K Genant, D van der Heijde, M Dougados

991 Preliminary definitions of ‘flare’ in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative

L Cosse, A Porter, R Landewé, A Echeto, V Navarro-Compte, F Krenn, D van der Heijde, M Dougados

997 Occupational exposure to textile dust increases the risk of rheumatoid arthritis: results from a Malaysian population-based case–control study

C L Too, N A Mukhamad, A Ilan, J Padubov, I Alfordsson, L Klarskov, S Munir, C Bengsson, MyERa Study Group

1003 The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis

C N Hatteved, J C Thorne, J E Pope, D Law, D Tin, G Bore, B Harana, C A Hitchen, E C Keyseate, S Jamal, V P Bykerk, for the CATCH Investigators

1009 Efficacy of sildenafil on ischaemic diabetic ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study


1016 Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study


1024 Comparing the effects of tocilizumab, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naïve, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques

P G Canagaph, M Ostergaard, M A Borens, C Wu, T Fuerst, D van der Heijde, F Brouxe-Paludouk, O Soto-Ratere, P Huyg, Z Xe, R Zhang, B T Wyman, J D Bradley, K Soma, B Willenon

1034 Predictive validity of the ASAS classification criteria for axial and peripheral spondylarthritis after follow-up in the ASAS cohort: a final analysis


---

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics. ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors’ institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

**Copyright:** © 2016 BMJ Publishing Group and European League Against Rheumatism. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission.

ARD is published by BMJ Publishing Group Ltd. Printed by Nova Techset Private Limited, Bengaluru & Chennai, India and printed in the UK on acid-free paper.

The changing landscape of biosimilars in rheumatology

T Denier, V Strand, P Cornelis, J Goncalves, L Caldas, J Kaye, T K Kost, J Smolarek, Y Tanaka, G R Burmester

### MORE CONTENTS

This article has been chosen by the Editor to be of special interest and is freely available online.

This article has been made freely available online under the BMJ Journals Open Access scheme. See [http://ard.bmj.com/sites/about/guidelines.xhtml#open](http://ard.bmj.com/sites/about/guidelines.xhtml#open) for more details.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics. See [http://publicationethics.org/](http://publicationethics.org/) for more details.

The online version of this article contains multiple choice questions hosted on BMJ Learning.
DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis
P Coit, I B De Lore, B Nan, V M Ehne, A H Sawaiha

Inactivation of autophagy ameliorates glucocorticoid-induced and ovariectomy-induced bone loss
N V Lin, C-W Chen, R Kagwrara, R Liang, G Beyr, A Distler, J Luther, K Engellé, G Schett, J HW Distler

Deficiency of sorting nexin 10 prevents bone erosion in collagen-induced mouse arthritis through promoting NFATc1 degradation
C Zhou, Y You, W Shen, Y-Z Zhu, J Peng, H-T Feng, Y Wang, D Li, W-W Shao, C-X Li, W-Z Li, J Xu, X Shen

Alpha-1-anti-trypsin-Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of IL-1β and by the induction of endogenous IL-1Ra
L A B Joosten, T O Cris, T Azam, M C P Cleophas, M I Koenders, F L van de Veerdonk, M G Netea, S Kim, C A Dinarello

Agrin mediates chondrocyte homeostasis and requires both LRP4 and α-dystroglycan to enhance cartilage formation in vitro and in vivo
S Eldridge, G Nalesso, H Ismail, K Vicente-Greco, P Kafouvides, M Ramachandran, A Niemeier, J Herz, C Pitzalis, M Perretti, F Dell’Aco

Neutrophil microvesicles resolve gout by inhibiting C5a-mediated priming of the inflammasome
A Campbell, B Ask, D Zeiler, J A Schifferli

Blocking the tropomyosin receptor kinase A (TrkA) receptor inhibits pain behaviour in two rat models of osteoarthritis
L N Nwosu, P I Mapp, V Chapman, D A Walsh

Crystal structure of Porphyromonas gingivalis peptidylarginine deiminase: implications for autoimmunity in rheumatoid arthritis
N A Burgess-Brown, R Fischer, W W Yue, P J Venables

Five-year follow-up of radiographic sacroiliitis: progression as well as improvement?
A Sepriano, M Rudwaleit, J Sieper, R van den Berg, R Landewé, D van den Heuvel

Reliability of the quantitative assessment of peripheral blood perfusion by laser speckle contrast analysis in a systemic sclerosis cohort
V Lambrecht, M Cataldi, F De Kuyser, S Decuman, B Ruaro, A Sulli, E Deschepper, V Smith

Towards standardisation of histopathological assessments of germinal centres and lymphoid structures in primary Sjögren’s syndrome
M R Hillen, F Barone, T R D J Radstake, J AG van Roon

Need for consensus guidelines to standardise the assessment of germinal centres and other histopathological parameters in salivary gland tissue of patients with primary Sjögren’s syndrome
K Delli, E A Haacke, T R D J Radstake, J AG van Roon

Do high numbers of salivary gland-infiltrating B cells predict better or worse outcomes after rituximab in patients with primary Sjögren’s syndrome?
D Corme, S Costa, V Derascht-Pensic, L Chiche, A Sanaai, J-O Pers

In primary Sjögren’s syndrome high absolute numbers and proportions of B cells in parotid glands predict responsiveness to rituximab as defined by ESSDAI, but not by SSRI
K Delli, E A Haacke, F GM Kroese, R P Pollard, S Ihrler, B van der Vegt, A Vissink, H Botoma, F K L Spijkervet